Efficacy and Safety of Ramucirumab Plus Carboplatin and Paclitaxel in Untreated Metastatic Thymic Carcinoma: RELEVENT Phase II Trial (NCT03921671)
C. Proto,M. Ganzinelli,S. Manglaviti,M. Imbimbo,G. Galli,M. Marabese, F. Zollo,M. F. Alvisi,M. Perrino, N. Cordua, F. Borea,F. de Vincenzo,A. Chella, S. Cappelli, E. Pardini,Z. Ballatore,A. Lucarelli,E. Ambrosini,M. Giuliano,E. Pietroluongo,C. Mulargiu,A. Fabbri,A. Prelaj,M. Occhipinti,M. Brambilla,L. Mazzeo,T. Beninato,R. Vigorito, M. Ruggirello,F. G. Greco,G. Calareso,D. Miliziano,E. Rulli, I. De Simone,V. Torri,F. G. M. de Braud,G. Pasello,P. De Placido,R. Berardi,I. Petrini,P. Zucali,M. C. Garassino,G. Lo Russo ANNALS OF ONCOLOGY（2024）
关键词
thymic carcinoma,ramucirumab,antiangiogenics,fi rst line,chemotherapy
AI 理解论文
溯源树
样例
